Nitisinone for the treatment of hereditary tyrosinemia type i

Expert Opinion on Orphan Drugs

Volumn 1, Issue 6, 2013, Pages 491-497

  McKiernan, Patrick James ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Guidelines; Inherited metabolic disease; Liver disease; Liver transplantation; Neonatal screening; Nitisinone; Tyrosinemia

Indexed keywords

ALPHA FETOPROTEIN; NITISINONE; PHENYLALANINE; PORPHOBILINOGEN; TYROSINE;

ACUTE LIVER FAILURE; ARTICLE; CARDIOMYOPATHY; CHEMISTRY; CHRONIC LIVER DISEASE; COMPASSIONATE USE; CORNEA BURN; CORNEA EROSION; DIET RESTRICTION; DRUG MONITORING; ENZYME ACTIVITY; ERYTHEMA; ERYTHROCYTE; ERYTHRODERMA; FETOTOXICITY; HEPATOBLASTOMA; HISTORY; HUMAN; HYPERINSULINISM; INCIDENCE; KIDNEY DISEASE; LEARNING DISORDER; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; METABOLIC REGULATION; NEUROLOGIC DISEASE; NEUROLOGICAL CRISES; NEWBORN PERIOD; NEWBORN SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; PHARMACODYNAMICS; PHARMACOKINETICS; PHENOTYPE; PHOTOPHOBIA; PLASMA HALF LIFE; POPULATION; PORTAL HYPERTENSION; PREGNANCY; PRURITUS; RENAL DYSFUNCTION; THERAPY EFFECT; THROMBOCYTOPENIA; TYROSINEMIA; TYROSINEMIA TYPE 1;

EID: 84896710759     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2013.800807     Document Type: Article

References (37)

1. McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006;66(6):743-50
2. Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CRBALSWSVD, editor. The metabolic and molecular bases of inherited disease. McGraw-Hill; New York: 2001. p. 1777-805
3. Castilloux J, Laberge AM, Martin SR, et al. "Silent" tyrosinemia presenting as hepatocellular carcinoma in a 10-year-old girl. J Pediatr Gastroenterol Nutr 2007;44(3):375-7
4. Nobili V, Jenkner A, Francalanci P, et al. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome. Pediatrics 2010;126(1):e235-8
5. de Laet C, Dionisi-Vici C, Leonard JV, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis 2013;8(1):8.
6. Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis 2000;4(4):805-14
7. Larochelle J, Alvarez F, Bussieres JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab 2012;107(1-2):49-54
8. De Laet C, Munoz VT, Jaeken J, et al. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1. Dev Med Child Neurol 2011;53(10):962-4
9. Masurel-Paulet A, Poggi-Bach J, Rolland MO, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008;31(1):81-7.
10. Thimm E, Richter-Werkle R, Kamp G, et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis 2012;35(2):263-8
11. Lock EA, Ellis MK, Gaskin P, et al. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4- trifluoromethylbenzoyl)- 1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inherit Metab Dis 1998;21(5):498-506
12. Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992;340(8823):813-17
13. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000555/WC500049195.pdf 2013
14. Hall MG, Wilks MF, Provan WM, et al. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4- fluoromethylbenzoyl)-1,3- cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol 2001;52(2):169-77
15. Schlune A, Thimm E, Herebian D, Spiekerkoetter U. Single dose NTBC-treatment of hereditary tyrosinemia type I. J Inherit Metab Dis 2012;35(5):831-6
16. la Marca G, Malvagia S, Materazzi S, et al. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I. Anal Chem 2012;84(2):1184-8
17. Holme E, Lindstedt S. Tyrosinaemia type I and NTBC (2-(2-nitro-4- trifluoromethylbenzoyl)-1,3- cyclohexanedione). J Inherit Metab Dis 1998;21(5):507-17
18. Santra S, Preece MA, Hulton SA, McKiernan PJ. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis 2008;31(3):399-402
19. Couce ML, Dalmau J, del Toro M, et al. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome. Pediatr Int 2011;53(6):985-9
20. El Karaksy H, Fahmy M, El Raziky M, et al. Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases. World J Pediatr 2011;7(3):224-31
21. Santra S, Baumann U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother 2008;9(7):1229-36
22. Crone J, Moslinger D, Bodamer OA, et al. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I. Acta Paediatr 2003;92(5):625-8
23. van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2- (2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 2005;40(1):90-3
24. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 1976;88(3):434-8
25. van Spronsen FJ, Thomasse Y, Smit GP, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994;20(5):1187-91.
26. Gibbs TC, Payan J, Brett EM, et al. Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase. J Neurol Neurosurg Psychiatry 1993;56(10):1129-32
27. Baumann U, Preece MA, Green A, et al. Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis 2005;28(2):131-5
28. Arora N, Stumper O, Wright J, et al. Cardiomyopathy in tyrosinaemia type I is common but usually benign. J Inherit Metab Dis 2006;29(1):54-7
29. Bartlett DC, Preece MA, Holme E, et al. Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1. J Inherit Metab Dis 2013;36(1):15-20
30. Garcia SN, Roche S, Imbard A, et al. Maternal and fetal tyrosinemia type I. J Inherit Metab Dis 2012; Epub ahead of print
31. Vanclooster A, Devlieger R, Meersseman W, et al. Pregnancy during nitisinone treatment for tyrosinaemia type I: first human experience. JIMD Rep 2012;5:27-33.
32. Koelink CJ, van Hasselt P, van der PA, et al. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer? Mol Genet Metab 2006;89(4):310-15
33. Gissen P, Preece MA, Willshaw HA, McKiernan PJ. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. J Inherit Metab Dis 2003;26(1):13-16
34. Ellaway CJ, Holme E, Standing S, et al. Outcome of tyrosinaemia type III. J Inherit Metab Dis 2001;24(8):824-32
35. Cerone R, Fantasia AR, Castellano E, et al. Pregnancy and tyrosinaemia type II. J Inherit Metab Dis 2002;25(4):317-18
36. Thimm E, Herebian D, Assmann B, et al. Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I. Mol Genet Metab 2011;102(2):122-5
37. Introne WJ, Perry MB, Troendle J, et al. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab 2011;103(4):307-14